This result indicated that the therapeutic effects of miR‐486 treatment in MI, such as promoting cardiac angiogenesis and increasing the expression of p53 and p16, cannot be attributed to SRSF3 as the target gene. The gene discussed is TP53; the disease is myocardial infarction.